CryoPort, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX) have been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $16.3750.

A number of research firms have recently commented on CYRX. Craig Hallum boosted their price objective on CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, June 3rd. Weiss Ratings raised CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Guggenheim raised their target price on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, BTIG Research lifted their price target on shares of CryoPort from $17.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, July 24th.

Insider Activity

In other news, insider Edward J. Zecchini sold 33,600 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total transaction of $486,192.00. Following the completion of the sale, the insider directly owned 109,719 shares of the company’s stock, valued at $1,587,633.93. This trade represents a 23.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Robert Stefanovich sold 169,427 shares of CryoPort stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total value of $2,756,577.29. Following the completion of the transaction, the chief financial officer owned 109,850 shares in the company, valued at $1,787,259.50. The trade was a 60.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 227,641 shares of company stock worth $3,622,515. Insiders own 9.50% of the company’s stock.

Institutional Trading of CryoPort

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in shares of CryoPort by 23.8% in the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after buying an additional 623,896 shares during the period. Vanguard Group Inc. lifted its position in shares of CryoPort by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock valued at $27,094,000 after acquiring an additional 69,550 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of CryoPort by 0.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,495,683 shares of the company’s stock valued at $12,384,000 after acquiring an additional 8,280 shares in the last quarter. UBS Group AG boosted its stake in CryoPort by 6.8% in the 4th quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock worth $13,650,000 after purchasing an additional 90,363 shares during the period. Finally, Mak Capital One LLC boosted its stake in CryoPort by 46.6% in the 4th quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock worth $11,513,000 after purchasing an additional 381,063 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

CryoPort Price Performance

NASDAQ CYRX opened at $15.09 on Friday. CryoPort has a 12 month low of $6.69 and a 12 month high of $16.89. The firm has a market capitalization of $760.57 million, a PE ratio of 11.18 and a beta of 1.88. The company’s 50 day simple moving average is $15.43 and its 200 day simple moving average is $11.77.

CryoPort (NASDAQ:CYRX) last released its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $47.80 million during the quarter, compared to analyst estimates of $44.86 million. CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%. Sell-side analysts anticipate that CryoPort will post -0.85 earnings per share for the current fiscal year.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.